Non-small cell lung cancer
Conditions
Interventions
Experimental group:Drug-loaded microsphere embolization therapy
Sponsors
Shanghai Pulmonary Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: (1) Non-small cell lung cancer confirmed by histology or cytology, and chest CT within 1 week shows that the distal part of the main lesion is combined with obstructive inflammation or obstructive atelectasis (2) There is at least one measurable lesion (evaluated according to RECIST1.1 standards) with clinical TNM stage III and above. The staging should be based on the 8th edition of the International Union Against Cancer (UICC) staging criteria. (3) Non-small cell lung cancer patients who have failed standard second-line treatment based on the "Guidelines for Diagnosis and Treatment of Lung Cancer (2022 Edition)" (4) Age: 18-85 years old (5) There are no significant abnormalities in laboratory tests (blood routine, liver and kidney function, coagulation function, etc.): ?Routine blood examination standards must meet the following standards WBC=3.0×109/L; PLT=100×109/L; HGB=10.0g/L; NEUT#=1.5×109/L ?Biochemical examination must meet the following standards: liver function: ALT, AST= 1.5 ULN; b. BIL=1.5 ULN; Kidney function: Cr=1.5 ULN; b. BUN: 2.86-7.14mmol/L (6) ECOG = 3 points (7) Expected survival = 3 months (8) The subjects voluntarily joined this study, signed the informed consent form, had good compliance, and cooperated with the follow-up
Exclusion criteria
Exclusion criteria: (1) Patients with other malignant tumors (2) Uncontrolled remote metastasis (3) Patients with a history of major diseases involving the heart, kidneys, liver, bone marrow, or central nervous system (4) Patients with uncontrolled diabetes, hypertension or ischemic heart disease (5) Pregnant or lactating women (6) The researcher determines that the clinical conditions are not suitable for D-BACE (arterial puncture contraindications) (7) Patients with obvious arteriovenous fistula (8) Preoperative CTA showed no obvious tumor supplying arteries to the systemic circulation. (9) Those who are allergic to vinorelbine or those who are severely allergic to iodine contrast media (10) Patients who, according to the researcher’s judgment, have concomitant diseases that seriously endanger patient safety or affect patients’ completion of the study (11) Patients who are currently participating in or participated in other clinical trials within 4 weeks before surgery (12) Patients with mental illness or history of psychotropic drug abuse
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR; | — |
Secondary
| Measure | Time frame |
|---|---|
| OS;PFS;Improvement rate of pulmonary obstructive lesions;AE;Quality of life score; | — |
Countries
China
Contacts
Public ContactSen Jiang
Shanghai Pulmonary Hospital
Outcome results
None listed